Skip to content
RS Oncology
News
RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma
June 3, 2024
RS Oncology Data for Novel Treatment of Aggressive Cancers Selected for an Oral Presentation at ASCO Annual Meeting
May 1, 2024
RS Oncology to present translational data identifying potential biomarkers associated with RSO-021 anticancer activity.
April 1, 2024
Recent advancements in treating malignant pleural mesothelioma, and why localized treatment could be advantageous
March 4, 2024
RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung
February 1, 2024
RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patient
August 3, 2023
AACR 2023, RSO-021, a first-in-class treatment
April 15, 2023
Mesothelioma UK
September 21, 2022
ESMO CONGRESS September 2022
August 22, 2022
RS Oncology, LLC Announces Initiation of Patient Dosing in Phase 1/2 MITOPE Clinical Trial of RSO-2
April 4, 2022
